康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

休市中 06-26 16:08:11

83.300

-2.150

-2.52%

最高86.500	最低80.800	成交量1,202万
今开86.000	昨收85.450	日振幅6.67%
总市值767.19亿	流通市值767.19亿	总股本9.21亿
成交额9.98亿	换手率1.31%	流通股本9.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":83.3,"timestamp":1782461291011,"preClose":85.45,"halted":0,"volume":12023737,"delay":0,"changeRate":-0.025160912814511476,"floatShares":921000000,"shares":921000000,"eps":-1.4211623081797506,"marketStatus":"休市中","change":-2.15,"latestTime":"06-26 16:08:11","open":86,"high":86.5,"low":80.8,"amount":998499214,"amplitude":0.066706,"askPrice":83.3,"askSize":113000,"bidPrice":83.1,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-1.4211623081797506,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782696600000},"marketStatusCode":7,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":85.45,"openAndCloseTimeList":[[1782437400000,1782446400000],[1782450000000,1782460800000]],"volumeRatio":0.7716740969345868,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.7094,"impliedVolPercentile":0.9057},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"1185489369","title":"异动解读｜康方生物盘中下跌3.16%，ASCO利好兑现后抛压持续叠加股价逼近52周低点","url":"https://stock-news.laohu8.com/highlight/detail?id=1185489369","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185489369?lang=zh_cn&edition=full","pubTime":"2026-06-26 10:29","pubTimestamp":1782440940,"startTime":"0","endTime":"0","summary":"6月26日，康方生物盘中下跌3.16%，报82.85港元，成交额3.75亿港元，股价持续承压逼近52周低点80.2港元。消息面上，公司此前于ASCO公布依沃西HARMONi-6 OS阳性数据后持续遭遇获利了结，股价较数据公布后高点累计跌幅已逾30%，尽管董事会批准最多2亿港元回购计划及管理层拟增持不超过5000万港元，短期抛压仍未消化。同板块中信达生物跌1.25%、荣昌生物跌0.86%，生物科技板块整体偏弱，行业beta拖累叠加个股利好兑现后的筹码松动共同加剧调整压力。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144312213","title":"异动解读｜康方生物盘中下跌3.43%，ASCO利好兑现后抛压反复叠加生物科技板块再度走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1144312213","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144312213?lang=zh_cn&edition=full","pubTime":"2026-06-25 09:55","pubTimestamp":1782352550,"startTime":"0","endTime":"0","summary":"6月25日，康方生物盘中下跌3.43%，报84.0港元，成交额1.81亿港元，股价再度逼近前期52周低点区域。消息面上，公司此前于ASCO公布依沃西HARMONi-6 OS阳性数据后持续遭遇获利了结，股价较数据公布后高点累计跌幅已逾30%，尽管公司董事会批准最多2亿港元回购计划及管理层拟增持不超过5000万港元，短期抛压仍未消化完毕。同日生物科技板块整体承压，科济药业跌4.53%、荣昌生物跌3.34%、信达生物跌2.63%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646840322","title":"【券商聚焦】中信证券：中国创新药BD交易金额超预期增长 即将进入密集数据催化期","url":"https://stock-news.laohu8.com/highlight/detail?id=2646840322","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646840322?lang=zh_cn&edition=full","pubTime":"2026-06-25 09:03","pubTimestamp":1782349398,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研报指，2026年以来，中国创新药BD交易金额超预期增长，产业全球竞争力进一步提升；国内市场快速放量，从2025年报来看，头部创新药企业在新产品驱动下，创新药收入快速增长，Biopharma陆续进入盈利拐点。研报认为创新药产业全球价值凸显，接下来将进入密集数据催化期。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984448","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002562.SGD","LU0359202008.SGD","LU0540923850.HKD","02269","01093","06160","IE0008368742.USD","LU0823426480.USD","LU1794554557.SGD","LU2039709279.SGD","LU2097828474.EUR","LU0856984785.SGD","SG9999004220.SGD","01801","SG9999002463.SGD","06978","BD","LU0348767384.USD","06030","LU0181495838.USD","600030","BK0196","LU0501845795.SGD","LU1242518857.USD","IE00B0JY6N72.USD","LU2328871848.SGD","02616","BK0028","01877","LU0405327148.USD","IE00B031HY20.USD","LU1064130708.USD","09688","IE00B5MMRT66.SGD","06185","09995","LU1813983027.USD","02142","LU0327786744.USD","LU1997245094.SGD","LU2289578879.USD","09926","LU1960683339.HKD","01177","159992","LU1226288253.USD","BK1610","LU1328277881.USD","BK1574","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111037845","title":"异动解读｜康方生物盘中上涨3.1%，多券商密集发布增持买入评级叠加生物科技板块集体反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1111037845","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111037845?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:48","pubTimestamp":1782265710,"startTime":"0","endTime":"0","summary":"6月24日，康方生物盘中上涨3.1%，报88.25港元，成交额2.42亿港元。消息面上，中信建投与兴业证券近日密集发布研报，分别给予\"买入\"及\"增持\"评级，叠加生物科技板块集体走强共同推动股价反弹。此外，公司董事会此前批准最多2亿港元回购计划及管理层拟增持不超过5000万港元，产业资本护盘信号明确。同板块中科伦博泰生物涨6.88%、荣昌生物涨4.11%、百济神州涨3.6%，行业整体回暖。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645987883","title":"【券商聚焦】中信建投证券维持康方生物(09926)“买入”评级 指其确立双重战略方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2645987883","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645987883?lang=zh_cn&edition=full","pubTime":"2026-06-23 14:43","pubTimestamp":1782197030,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投发布研报指，康方生物 凭借全球领先的Tetrabody双抗技术平台，已确立“IO 2.0 + ADC”的双重战略方向，形成“双抗基石+下一代ADC+新型免疫调节剂”的梯次布局，是具备全球竞争力的综合性创新药领军企业。考虑到公司创新药产品疗效优秀、市场空间广阔，给予“买入”评级。风险提示包括行业政策、研发及审批不及预期、销售不及预期等。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984283","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645388004","title":"中信建投：予康方生物(09926)“买入”评级 多引擎突破全新增长曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2645388004","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645388004?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:23","pubTimestamp":1782181394,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投发布研报称，考虑到公司创新药产品疗效优秀、市场空间广阔，给予康方生物“买入”评级。中信建投主要观点如下：核心观点康方生物凭借全球领先的双抗技术平台和全面一体化的研发能力，已成长为国内双抗领域的龙头，并正向全球创新药领军者迈进。2025年公司产品销售收入同比增长51.5%至30.33亿元，五款自研新药合计12项适应症全部纳入国家医保，商业化实现量质齐升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457332.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645001206","title":"医药板块逆市走高 山东新华制药(00719)涨23.59%、康诺亚-B(02162)涨5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645001206","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645001206?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:08","pubTimestamp":1782180500,"startTime":"0","endTime":"0","summary":"市场交易结构出现变化，医药与科技板块不再呈现明显跷跷板效应，医疗服务、CXO赛道带动板块韧性修复。临近二季度末，市场开始提前交易行业业绩预期，资金重点布局两大主线，分别为商业化放量提速的创新药标的，以及受益于投融资回暖的CXO、生命科学上游龙头。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984274","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","09926","LU0456827905.SGD","LU1880383366.USD","BK1589","02162","BK1583","BK1576","LU1720050803.USD","LU0307460666.USD","09995","IE00B0JY6N72.USD","LU0326950275.SGD","IE00BPRC5H50.USD","LU0039217434.USD","01877","159938","LU3063872942.SGD","LU1303224171.USD","LU0856984785.SGD","02268","LU0588546209.SGD","LU0051755006.USD","BK1161","LU0359202008.SGD","LU0516423091.SGD","02269","LU0516422952.EUR","LU1251922891.USD","LU2328871848.SGD","LU0456846285.SGD","LU0320764599.SGD","LU0327786744.USD","LU0516422366.SGD","09939","06160","LU0348783233.USD","06990","LU0052750758.USD","09969","LU0359201612.USD","LU0979878070.USD","LU0140636845.USD","LU0417516902.SGD","09688","LU1242518857.USD","LU2039709279.SGD","SG9999002562.SGD","00719","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118067406","title":"异动解读｜康方生物盘中上涨3.44%，逼近52周低点后回购护盘叠加券商维持增持评级触发反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1118067406","media":"行情直击","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118067406?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:38","pubTimestamp":1782178726,"startTime":"0","endTime":"0","summary":"6月23日，康方生物盘中上涨3.44%，报85.85港元，成交额1.15亿港元。消息面上，公司股价前一交易日一度跌至82.5港元逼近52周低点82.85港元，技术面超卖修复叠加产业资本护盘共同触发反弹。此前公司董事会批准最多2亿港元回购计划及管理层拟增持合计不超过5000万港元。同时兴业证券最新研报维持\"增持\"评级，认为依沃西HARMONi-6 OS数据具里程碑意义，预计其2033年前有望实现150亿美元以上收入，基本面支撑信号明确。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645041454","title":"【券商聚焦】兴业证券维持康方生物(09926)“增持”评级 指依沃西OS数据具里程碑意义","url":"https://stock-news.laohu8.com/highlight/detail?id=2645041454","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645041454?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:09","pubTimestamp":1782112147,"startTime":"0","endTime":"0","summary":"金吾财讯 | 兴业证券发布研报指，康方生物 于2026年ASCO年会公布的HARMONi-6研究OS数据显著阳性。中位随访21.4个月，数据尚未完全成熟，但24个月OS率差距持续扩大，展现出长期生存拖尾效应。该OS数据落地消除了市场对PFS优势能否转化为OS获益的疑虑，具有里程碑意义。研报认为，依沃西在中国和全球研究数据高度一致，HARMONi-6结果提振了全球注册临床HARMONi-3的成功信心。预计依沃西2033年前有望实现150亿美元以上收入。维持“增持”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984173","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601377","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196903514","title":"异动解读｜康方生物盘中下跌3.88%，ASCO利好兑现后抛压延续叠加板块整体承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1196903514","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196903514?lang=zh_cn&edition=full","pubTime":"2026-06-22 09:44","pubTimestamp":1782092666,"startTime":"0","endTime":"0","summary":"6月22日，康方生物盘中下跌3.88%，报82.5港元，成交额1.6亿港元，股价逼近52周低点82.85港元。此前公司董事会批准最多2亿港元回购计划及管理层拟增持合计不超过5000万港元未能有效扭转颓势。叠加美方可能限制对中国生物技术投资的传闻扰动，生物科技板块整体承压，行业内科伦博泰生物跌6.3%、信达生物跌4.46%、三生制药跌4.44%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644314776","title":"创新药概念普涨 再鼎医药(09688)升逾6% 机构指该板块仍将为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2644314776","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644314776?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:21","pubTimestamp":1781749308,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念普涨，截至发稿，再鼎医药 涨6.34%，康方生物涨5.96%，药明康德涨3.59%，康诺亚-B涨3.49%，亚盛医药涨3.45%，药明生物涨3.08%，金斯瑞生物科技涨2.93%，百济神州涨2.60%。华鑫证券研究称，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984066","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","02269","LU2328871848.SGD","LU2242644610.SGD","LU2488822045.USD","LU0348827113.USD","BK1589","06160","LU0516423174.USD","LU2476274308.USD","LU0979878070.USD","09926","BK1161","LU1720050803.USD","IE00BPRC5H50.USD","LU0516422366.SGD","BK1588","LU0516422952.EUR","159992","LU0326950275.SGD","LU0348784397.USD","LU0561508036.HKD","02162","BK1587","BK4526","HK0000306685.HKD","LU0307460666.USD","LU0417516571.SGD","LU0588546209.SGD","LU1969619763.USD","09688","HK0000306701.USD","HK0000320223.HKD","LU1961090484.USD","ZLAB","LU1303224171.USD","BK1583","BK1141","LU0516423091.SGD","LU2045819591.USD","06978","LU1719994722.HKD","06855","LU0456846285.SGD","LU0140636845.USD","01548","02359","BK4531","SG9999002463.SGD","LU1794554557.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177778204","title":"港股创新药概念股盘中走高！再鼎医药涨超6%，康方生物涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177778204","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177778204?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:20","pubTimestamp":1781749207,"startTime":"0","endTime":"0","summary":"6月18日，港股创新药概念股盘中走高，$再鼎医药(ZLAB)$涨超6%，$康方生物(09926)$涨超5%，$亚盛医药(06855)$、$百济神州(06160)$、$药明生物(02269)$、$药明康德(02359)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","IE00B543WZ88.USD","BK1161","LU0417516571.SGD","LU1720050803.USD","LU0348827113.USD","LU2778985437.USD","09926","LU2476274308.USD","159992","LU0348766576.USD","LU0348825331.USD","LU0634319403.HKD","BK4531","LU0561508036.HKD","LU2399975544.HKD","LU1794554557.SGD","LU1961090484.USD","LU2488822045.USD","BK4139","BK4588","LU0348767384.USD","VXUS","IE00B5MMRT66.SGD","LU0348735423.USD","LU0348783233.USD","LU0417516902.SGD","LU0348784397.USD","LU0417516738.SGD","BK4526","ZLAB","LU0540923850.HKD","BK4548","BK1588","06978","09688","BK4585","IE00BPRC5H50.USD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101175896","title":"异动解读｜康方生物盘中上涨3.64%，行业回购潮叠加板块超跌反弹推动股价企稳","url":"https://stock-news.laohu8.com/highlight/detail?id=1101175896","media":"行情直击","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101175896?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:05","pubTimestamp":1781748338,"startTime":"0","endTime":"0","summary":"6月18日，康方生物盘中上涨3.64%，报86.95港元，成交额2.18亿港元。消息面上，医药行业回购潮持续发酵，叠加创新药板块估值跌至历史低位后技术性反弹，推动股价企稳回升。此前公司董事会批准动用最多2亿港元在公开市场购买股份，管理层拟增持合计不超过5000万港元。康方生物此前因ASCO依沃西HARMONi-6 OS阳性结果兑现后持续获利了结，股价较数据公布后高点累计跌幅逾30%，当前技术面超卖修复与产业资本增持信号共同支撑反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644773208","title":"【券商聚焦】中信建投：生物制品板块跟随医药行业整体回调 考虑与资金因素有关","url":"https://stock-news.laohu8.com/highlight/detail?id=2644773208","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644773208?lang=zh_cn&edition=full","pubTime":"2026-06-18 09:26","pubTimestamp":1781745972,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究认为：1）中药：板块本周跑赢大盘及医药指数。市场关注呼吸道疾病发病率、基药目录等进展；除此市场持续关注“四同药品”价格专项治理、中成药集采等外部政策环境变化等带来的影响。2）生物制品：板块本周跑输医药指数及大盘。本周板块跟随医药行业整体回调，考虑主要与资金因素有关。3）医药商业：板块本周跑输申万医药，跑赢大盘。药店板块主要关注5月同店数据；流通板块关注院内合规及红利标的。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984059","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0640798160.USD","BK1515","LU1303224171.USD","LU0417516571.SGD","SG9999014674.SGD","09688","BK1191","IE00BPRC5H50.USD","LU0417516902.SGD","02196","LU2328871848.SGD","601066","BK1197","01789","BK1588","BK1585","03933","LU0348784397.USD","LU2476274308.USD","LU0348783233.USD","LU0561508036.HKD","LU1770034418.SGD","BK1500","LU0348735423.USD","LU2399975544.HKD","IE00B3M56506.USD","IE00B5MMRT66.SGD","LU0348766576.USD","LU0540923850.HKD","SG9999004311.SGD","02367","LU0348767384.USD","06821","LU1969619763.USD","09926","06160","BK1141","BK1161","LU1719994722.HKD","LU2476274720.SGD","02228","LU1720050803.USD","01530","LU0348827113.USD","01099","BK1207","LU0588546209.SGD","BK1100","BK1574","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131801510","title":"异动解读｜康方生物盘中下跌3.41%，回购短暂提振后ASCO利好兑现抛压再度主导","url":"https://stock-news.laohu8.com/highlight/detail?id=1131801510","media":"行情直击","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131801510?lang=zh_cn&edition=full","pubTime":"2026-06-16 09:38","pubTimestamp":1781573890,"startTime":"0","endTime":"0","summary":"6月16日，康方生物盘中下跌3.41%，报86.2港元，成交额8954.66万港元。消息面上，公司核心产品依沃西HARMONi-6研究OS阳性结果于6月1日ASCO全体会议公布后，事件驱动型资金持续获利了结，股价较数据公布后高点累计跌幅已逾30%。此前公司董事会批准最多2亿港元回购计划及管理层拟增持合计不超过5000万港元曾短暂提振股价，但抛压再度主导走势。叠加美方可能限制对中国生物技术投资的传闻扰动及市场对创新药盈利能力的担忧，生物科技板块整体承压。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110086674","title":"康方生物新一代HER3 ADC药物AK138d1联合依沃西单抗：首例患者入组Ib/II期乳腺癌研究，推进\"IO2.0 + ADC2.0\"战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1110086674","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110086674?lang=zh_cn&edition=full","pubTime":"2026-06-15 14:53","pubTimestamp":1781506404,"startTime":"0","endTime":"0","summary":"康方生物的新一代HER3靶向抗体偶联药物AK138d1，与依沃西单抗联合疗法的Ib/II期乳腺癌临床研究，已迎来首例患者入组。这一进展标志着公司\"免疫治疗2.0（IO2.0）与抗体偶联药物2.0（ADC2.0）\"双平台协同发展战略的实质性推进。该研究旨在评估这一创新联合疗法在HER3表达阳性晚期实体瘤，特别是乳腺癌患者中的安全性、耐受性及初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","LU0348825331.USD","LU0417516902.SGD","IE00BPRC5H50.USD","LU1794554557.SGD","LU0348784397.USD","LU0348766576.USD","LU0540923850.HKD","LU2778985437.USD","LU0417516738.SGD","BK1574","IE00B5MMRT66.SGD","LU0417516571.SGD","IE00B543WZ88.USD","LU2399975544.HKD","LU1720050803.USD","LU0348767384.USD","LU0634319403.HKD","BK1161","LU2476274720.SGD","LU2488822045.USD","LU0561508036.HKD","LU0348735423.USD","LU2476274308.USD","LU0348783233.USD","LU0348827113.USD","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150632681","title":"异动解读｜康方生物盘中下跌3.04%，回购计划短暂提振后ASCO利好兑现抛压再度主导","url":"https://stock-news.laohu8.com/highlight/detail?id=1150632681","media":"行情直击","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150632681?lang=zh_cn&edition=full","pubTime":"2026-06-15 14:22","pubTimestamp":1781504520,"startTime":"0","endTime":"0","summary":"6月15日，康方生物盘中下跌3.04%，报89.2港元，成交额13.48亿港元。此前公司董事会批准最多2亿港元回购计划曾短暂提振股价，但ASCO利好兑现后的持续抛压再度主导走势。消息面上，公司核心产品依沃西HARMONi-6研究OS阳性结果于6月1日ASCO全体会议公布后，事件驱动型资金持续获利了结，叠加美方可能限制对中国生物技术投资的传闻扰动及市场对创新药盈利能力的担忧，板块整体承压。尽管多家券商维持买入评级，资金面抛压仍主导短线走势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06078","IE00BZ08YR35.GBP","BK1576","LU1226287875.USD","LU1880383366.USD","02162","01548","01801","06996","LU0051755006.USD","02273","LU0502904849.HKD","03692","LU0181495838.USD","SG9999002562.SGD","LU0320764599.SGD","BK1191","LU0140636845.USD","IE00B0JY6N72.USD","LU0819121731.USD","LU2097828631.EUR","03329","02096","01093","LU1960683339.HKD","01952","LU1242518857.USD","06990","LU2399975544.HKD","HK0000320264.USD","00013","02269","02268","09996","LU0456827905.SGD","HK0000306685.HKD","02596","09966","03759","09926","LU0348827113.USD","01177","01951","LU0737861772.HKD","LU1688375341.USD","01530","LU3063872942.SGD","01276","06821","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642254781","title":"医药板块集体回升 科伦博泰生物(06990)涨7.20%、荣昌生物(09995)涨6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642254781","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642254781?lang=zh_cn&edition=full","pubTime":"2026-06-12 13:30","pubTimestamp":1781242214,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药板块集体回升，科伦博泰生物 涨7.20%，荣昌生物涨6.53%，康诺亚-B涨5.58%，复宏汉霖涨5.36%，康方生物涨5.07%，君实生物涨4.61%，药明合联涨4.06%，诺诚健华涨3.96%。英伟达同时为 Abridge 投资方，新模型基于英伟达开放模型套件 Nemotron 训练，Abridge 将采用去标识化临床数据进行定制优化，预计 2026 年晚些时候上线。东莞证券研报认为，受行业合规整顿以及消费疲软等因素影响，2025年医药生物行业整体归母净利润同比有所下滑。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983673","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","HK0000165453.HKD","LU0348783233.USD","LU2476274308.USD","BK1141","LU0417516738.SGD","IE00BPRC5H50.USD","LU1961090484.USD","06990","HK0000320264.USD","09995","LU1794554557.SGD","HK0000320223.HKD","LU2148510915.USD","HK0000306701.USD","LU0634319403.HKD","09926","LU1064130708.USD","LU2488822045.USD","LU0348766576.USD","BK1587","01877","LU0417516571.SGD","BK1515","BK1583","02162","159938","LU2399975544.HKD","688331","LU1720050803.USD","LU0348767384.USD","02268","LU0561508036.HKD","LU1064131003.USD","LU2328871848.SGD","LU0540923850.HKD","LU1969619763.USD","02696","BK1574","LU0417516902.SGD","09969","LU2476274720.SGD","09939","HK0000306685.HKD","LU0348827113.USD","LU0348784397.USD","LU0348825331.USD","SG9999014674.SGD","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642640584","title":"康方生物(09926)拟斥资最多2亿港元回购股份 执行董事及高级管理层拟增加持股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642640584","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642640584?lang=zh_cn&edition=full","pubTime":"2026-06-11 12:06","pubTimestamp":1781150805,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布公告，于2026年6月11日，本公司董事会批准动用最多2亿港元以在公开市场上购买本公司普通股(股份)。建议购买股份将由本公司 2021年受限制股份单位计划的受托人执行。建议购买股份显示董事会及管理层对本公司业务展望及前景充满信心，并将从而惠及本公司，为股东创造价值。建议购买股份将由本公司现有可用现金资源拨付。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","LU0417516571.SGD","IE00BPRC5H50.USD","LU0417516902.SGD","LU0348784397.USD","IE00B543WZ88.USD","LU2476274308.USD","LU0417516738.SGD","LU1794554557.SGD","LU1961090484.USD","LU0348783233.USD","LU2488822045.USD","LU0561508036.HKD","LU2399975544.HKD","LU0348735423.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0348766576.USD","LU0540923850.HKD","LU0348767384.USD","09926","LU2476274720.SGD","BK1161","LU0348825331.USD","LU1720050803.USD","LU0348827113.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.0485},{"period":"1month","weight":-0.2769},{"period":"3month","weight":-0.341},{"period":"6month","weight":-0.2602},{"period":"1year","weight":-0.1218},{"period":"ytd","weight":-0.2628}],"compareEarnings":[{"period":"1week","weight":-0.0524},{"period":"1month","weight":-0.1049},{"period":"3month","weight":-0.0914},{"period":"6month","weight":-0.1219},{"period":"1year","weight":-0.068},{"period":"ytd","weight":-0.1154}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.021305},{"month":6,"riseRate":0.571429,"avgChangeRate":0.072106},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}